This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (23)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 2002;120:502-508.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Idiopathic polypoidal choroidal vasculopathy (IPCV), a peculiar hemorrhagic disorder of the macula involving serosanguineous detachments of the retinal pigment epithelium (RPE) and neurosensory retina, was first described by Yannuzzi¹ at a meeting of the Macula Society in 1982. At the American Academy of Ophthalmology in 1984, Kleiner and coworkers² described 7 patients with varying degrees of visual loss secondary to multiple recurrent hemorrhages or serous fluid beneath the RPE and neurosensory retina in the posterior fundus, and coined the phrase posterior uveal bleeding syndrome for this condition. In 1985, Stern and coworkers³ published the first report on "multiple recurrent serosanguineous RPE detachments" in 3 middle-aged black women. In his 1987 atlas, Gass⁴ described 3 black women with subretinal bleeding from multicentric neovascular networks with orange sub-RPE plaques or nodules in the peripapillary region.

Several additional reports and case series^5-11 and 2 clinicopathologic studies^12-13 have been published. The previously published pathologic . . . [Full Text of this Article]

Report of a Case


Comment
Corresponding author and reprints: Robert H. Rosa, Jr, MD, Division of Ophthalmology, Scott and White Clinic, 2401 S 31st St, Temple, TX 76508 (e-mail: rrosa@swmail.sw.org).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy
Lai et al.
Br. J. Ophthalmol. 2008;92:661-666.
ABSTRACT | FULL TEXT  

Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi et al.
Br. J. Ophthalmol. 2008;92:70-73.
ABSTRACT | FULL TEXT  

The origins of polypoidal choroidal vasculopathy
Yuzawa et al.
Br. J. Ophthalmol. 2005;89:602-607.
ABSTRACT | FULL TEXT  

Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho et al.
Arch Ophthalmol 2003;121:1392-1396.
ABSTRACT | FULL TEXT